Head of global research and development at Life Technologies
Professor of Systems Biology, Columbia University
Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Info and registration details here.
Alzheimer’s Disease devastates the lives of 25-40 million people worldwide — a number that is projected to quadruple in the coming decades. There are currently no FDA-approved medicines that can significantly modify the course of the disease. There is no effective means for early detection and diagnosis. Furthermore, neurodegeneration is among the mostly costly and risky areas of drug development. Yet, the high risk is balanced by high reward, and today Alzheimer’s is both an area of tremendous scientific promise and an exciting business opportunity.